KROS•benzinga•
Keros Therapeutics Presents Additional Clinical Data From Its KER-012 Program And Preclinical Data From Its KER-050 Program At The American Society Of Bone And Mineral Research 2022 Annual Meeting
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga